Advertisement
Organisation › Details
Noxxon (Group)
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. *
Start | 1997-01-01 established | |
End | 2022-07-15 renamed | |
Group | TME Pharma (Group) | |
Today | TME Pharma (Group) | |
Successor | TME Pharma (Group) | |
Industry | drug development technology | |
Industry 2 | Spiegelmer® technology | |
Person | Mangasarian, Aram (Noxxon 201005 CBO before Novexel since 200511 VP BusDev before ExonHit VP BusDev) | |
Person 2 | Buchanan, Iain (Noxxon 201009– interim CEO before Novexel CEO before Vertex Pharmaceuticals) | |
Region | Berlin | |
Country | Germany | |
Street | 8–10 Max-Dohrn-Str. | |
City | 10589 Berlin | |
Tel | +49-30-726247-0 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | C: 51 to 100 (2011-09-06) |
Currency | EUR | |
Profit | -5,390,000 (2017-12-31) | |
Cash | 622,000 (2017-12-31) | |
* Document for »About Section«: Noxxon Pharma N.V.. (10/27/21). "Press Release: Experienced Financial Executive, Bryan Jennings, Joins Noxxon as CFO". Berlin. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for TME Pharma (Group)
- [1] TME Pharma N.V.. (1/23/23). "Press Release: TME Pharma Provides Clinical Update on the GLORIA Expansion Arm Testing NOX-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma". Berlin....
- [2] Noxxon Pharma N.V.. (1/3/22). "Press Release: Noxxon Secures €17 Million Expansion of Equity-linked Facility with Atlas to Advance NOX-A12 in Glioblastoma and Pancreatic Cancer Programs [ corrected version of press release originally issued 29 Dec 2021 ...
- [3] Noxxon Pharma N.V.. (10/27/21). "Press Release: Experienced Financial Executive, Bryan Jennings, Joins Noxxon as CFO". Berlin....
- [4] Noxxon Pharma N.V.. (12/14/18). "Press Release: Noxxon Announces Key Findings that NOX-A12 plus Keytruda Induces an Immune Response and Results in Clinical Benefit for Patients". Berlin....
- [5] Noxxon Pharma N.V.. (11/16/18). "Press Release: Noxxon Announces € 6.2 Million Equity Capital Raise including US$ 5 Million from US Family Office – Acuitas Capital, LLC. Noxxon Ends the Use of Variable Rate Equity Financing with Yorkville". Berlin....
- [6] Noxxon Pharma N.V.. (10/23/18). "Press Release: Noxxon to Attend European Investor and Partnering Conferences in November 2018". Berlin....
- [7] Noxxon Pharma N.V.. (6/15/18). "Press Release: Noxxon Announces that It Has Secured Additional Financing". Berlin....
- [8] Noxxon Pharma N.V.. (10/3/17). "Press Release: Noxxon Publishes Preclinical Proof-of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors". Berlin....
- [9] Noxxon Pharma N.V.. (9/29/17). "Press Release: Noxxon Supervisory Board Elects Experienced US & EU Biotech Veteran Don deBethizy Chairman". Berlin....
- [10] Noxxon Pharma N.V.. (9/28/17). "Press Release: Noxxon Provides Update on Ongoing Phase 1/2 Clinical Trial with Lead Program NOX-A12". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top